A previous study showed that a two-gene prognostic model can accurately predict the prognosis of patients with chronic lymphocytic leukemia, in which SLAMF1 is a risk gene, and patients with high risk scores had a poorer prognosis than did those with low risk scores [29]. This evidence concerns the gene SLAMF1 and B-cell chronic lymphocytic leukemia.